Data & Publications
Independent Performance Data
Proof-of-concept results demonstrating how the Mirai™ platform delivers established respiratory molecules - benchmarked against reference listed drugs by an independent laboratory.
Mirai™ DPI Performance Testing
Budesonide Formulation vs. Reference Listed Drug
Independent laboratory testing conducted by Intertek demonstrates that the Mirai™ dry powder inhaler platform achieves near-equivalent aerodynamic particle size distribution (APSD) to established reference listed drugs within 1-2 development iterations.
The Next-Generation Capsule Inhaler
A technical paper examining why capsule inhalation is strategically relevant again, the limitations of conventional piercing devices, and the opportunity to use the opened capsule as a functional part of the aerosol pathway.
Knightpoint Opens Strategic Discussions for the Mirai™ Next-Generation Capsule Inhaler Following US and European Patent Grants
Knightpoint opens strategic discussions following US and European patent grants — a patented platform that opens rather than pierces capsules, combining dose-form economics, formulation flexibility and a fundamentally simpler inhaler architecture.
Why Capsules Could Be the Future of Inhalation
A strategic comparison of the three inhaler architectures — pMDI, MDPI and the Next-Generation Capsule Inhaler (NGCI) — and why the capsule creates a third strategic choice.
Respiratory Delivery Systems: A Sense of Perspective
Why device resistance to air flow is only one parameter in inhaler selection — and why formulation, patient handling and perception matter just as much.